NASDAQ$ONC
BeiGene Ltd-ADR · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
BeiGene's financial performance for Q3 2021 was reported, featuring significant revenue growth and key regulatory milestones.
BeiGene reported a strong third quarter with a 111% increase in product revenue compared to the prior year period. The company saw significant growth in sales of BRUKINSA and tislelizumab, along with the launch of a new product from the Amgen collaboration. BeiGene also achieved important regulatory milestones, including the FDA acceptance of the BLA for tislelizumab and approvals for BRUKINSA in new indications and markets.
- Product revenue increased by 111% year-over-year to $192.5 million, driven by internally developed products and in-licensed products from Amgen.
- Global sales of BRUKINSA rose by 320% to $65.8 million, with significant contributions from both U.S. and China markets.
- Tislelizumab sales in China increased by 54% to $77.0 million, fueled by new patient demand and market share expansion.
- The company's first biologics license application (BLA) in the U.S. for tislelizumab was accepted for review by the FDA.
Headline financials
Revenue & EPS history
BeiGene · Revenue · Quarterly
$206M
Revenue by segment
BeiGene · $65.8M total across 1 segment · Q3 2021
- BRUKINSA$65.8M+320.2%100.0%
Forward guidance
BeiGene anticipates several milestones in the near term, including regulatory approvals and clinical trial results.
Tailwinds
- Expected EMA approval for BRUKINSA in treating adult patients with WM in 2021.
- Reporting results from the Phase 3 SEQUOIA trial comparing BRUKINSA with bendamustine plus rituximab in patients with treatment-naïve CLL or SLL.
- Continue to discuss Phase 3 clinical trial results in CLL with regulatory agencies in the U.S., Europe, and other countries.
- Report additional results from the Phase 3 ALPINE trial in 2022.
- Receive approvals in China for the four sBLAs currently under review in first-line NPC, second- or third-line NSCLC, second-line ESCC, and second- or third-line MSI-High solid tumors in 2022.
Headwinds
- The Company expects that the worldwide health crisis of COVID-19 will continue to have a negative impact on its operations, including commercial sales, regulatory interactions, inspections, filings, and clinical trial recruitment, participation, and data read outs.
- Uncertainty regarding the future impact of the pandemic globally.
- BeiGene contests BMS-Celgene's termination of a license and supply agreement with respect to ABRAXANE® in China.
- Arbitration proceedings are ongoing between the parties regarding BMS-Celgene’s failure to ensure the continuity and adequacy of its supply of ABRAXANE under the agreement in accordance with Good Manufacturing Practices (GMP).
- Phase 2 trial evaluating investigational SARS-CoV-2 neutralizing antibody BGB-DXP593 in patients with mild to moderate COVID-19 did not meet the primary efficacy endpoint.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
-0.1%
Avg return
Earnings day
+0.1%
Avg return
5 days after
-2.0%
Avg return
30 days after
40%
16 / 40 earnings
Positive
+15.9%
Q4 2023
Best reaction
-9.6%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.3% | +4.3% | -9.4% | |
| Q4 2025 | -8.5% | -15.7% | -19.6% | |
| Q3 2025 | +3.4% | +6.9% | +0.5% | |
| Q1 2025 | -3.9% | -3.5% | +5.8% | |
| Q4 2024 | +7.5% | -0.7% | +3.2% | |
| Q3 2024 | +1.4% | -4.5% | +1.4% | |
| Q2 2024 | +6.8% | +10.9% | +11.7% | |
| Q1 2024 | -2.0% | -2.2% | -4.9% | |
| Q4 2023 | +15.9% | +6.4% | -0.0% | |
| Q3 2023 | -0.5% | +0.7% | -12.6% | |
| Q2 2023 | -0.3% | -9.2% | +1.2% | |
| Q1 2023 | -5.7% | -7.3% | -14.2% | |
| Q4 2022 | +4.2% | +11.9% | +2.9% | |
| Q3 2022 | -0.2% | +7.3% | +4.2% | |
| Q2 2022 | +14.6% | +16.4% | -1.7% | |
| Q1 2022 | -9.6% | -11.9% | -12.9% | |
| Q4 2021 | -2.5% | -0.8% | -10.8% | |
| Q3 2021 | -2.3% | -1.1% | -15.9% | |
| Q2 2021 | -6.3% | -8.1% | -2.0% | |
| Q1 2021 | +2.2% | +5.4% | +15.7% | |
| Q4 2020 | -4.4% | -8.5% | -3.0% | |
| Q3 2020 | -3.6% | -7.2% | -26.8% | |
| Q2 2020 | -2.9% | -7.7% | +5.8% | |
| Q1 2020 | +1.0% | +6.0% | +9.6% | |
| Q4 2019 | -2.3% | -3.2% | -21.8% | |
| Q3 2019 | +2.9% | +3.4% | -6.5% | |
| Q2 2019 | +1.6% | +3.9% | -7.8% | |
| Q1 2019 | +14.2% | +13.6% | +4.3% | |
| Q4 2018 | -2.1% | +8.4% | -5.7% | |
| Q3 2018 | +1.4% | -11.2% | +10.4% | |
| Q2 2018 | -3.7% | -4.4% | -4.7% | |
| Q1 2018 | -5.2% | +4.3% | +20.9% | |
| Q4 2017 | -4.8% | +0.3% | +11.3% | |
| Q3 2017 | -5.5% | -0.0% | +10.4% | |
| Q2 2017 | -7.3% | -9.0% | -7.4% | |
| Q1 2017 | -1.3% | +0.7% | +3.9% | |
| Q4 2016 | -2.8% | -4.1% | -3.1% | |
| Q3 2016 | -4.7% | +7.4% | -19.5% | |
| Q2 2016 | +0.8% | +6.0% | +11.0% | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro